Lucía Santa Maria de la Parra , Lucía M. Balsa , Ignacio E. León
{"title":"Metallocompounds as anticancer agents against osteosarcoma","authors":"Lucía Santa Maria de la Parra , Lucía M. Balsa , Ignacio E. León","doi":"10.1016/j.drudis.2024.104100","DOIUrl":null,"url":null,"abstract":"<div><p>Metallocompounds are a class of anticancer compounds largely used in the treatment of several types of solid tumors, including bone cancer. Osteosarcoma (OS) is a primary malignant bone tumor that frequently affects children, adolescents and young adults. It is a very invasive type of tumor, so ∼40% of patients develop distant metastases, showing elevated mortality rates. In this review, we present an outline of the chemistry and antitumor properties of metal-based compounds in preclinical (<em>in vitro</em> and <em>in vivo</em>) and clinical OS models, focusing on the relationship between structure–activity, molecular targets and the study of the mechanism of action involved in metallocompound anticancer activity.</p></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 9","pages":"Article 104100"},"PeriodicalIF":6.5000,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359644624002253","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Metallocompounds are a class of anticancer compounds largely used in the treatment of several types of solid tumors, including bone cancer. Osteosarcoma (OS) is a primary malignant bone tumor that frequently affects children, adolescents and young adults. It is a very invasive type of tumor, so ∼40% of patients develop distant metastases, showing elevated mortality rates. In this review, we present an outline of the chemistry and antitumor properties of metal-based compounds in preclinical (in vitro and in vivo) and clinical OS models, focusing on the relationship between structure–activity, molecular targets and the study of the mechanism of action involved in metallocompound anticancer activity.
金属化合物是一类抗癌化合物,主要用于治疗包括骨癌在内的几种实体瘤。骨肉瘤(Osteosarcoma,OS)是一种原发性恶性骨肿瘤,经常侵袭儿童、青少年和年轻人。骨肉瘤是一种侵袭性很强的肿瘤,40%的患者会发生远处转移,死亡率较高。在这篇综述中,我们概述了金属基化合物在临床前(体外和体内)和临床 OS 模型中的化学性质和抗肿瘤特性,重点介绍了金属化合物抗癌活性的结构-活性、分子靶点和作用机制研究之间的关系。
期刊介绍:
Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.
Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.